A phase II clinical trial of carbon-ion radiotherapy and concurrent S-1 chemotherapy for locally advanced pancreatic cancer (HIMAT1326)

A phase II clinical trial of carbon-ion radiotherapy and concurrent S-1 chemotherapy for locally advanced pancreatic cancer (HIMAT1326) - Carbon-ion radiotherapy with S-1 chemotherapy for locally advanced pancreatic cancer (HIMAT1326)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013803

Enrollment

Registered

2014-04-24

Start date

2014-04-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

locally advanced pancreatic cancer

Interventions

Carbon-ion radiotherapy Chemotherapy (S-1)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically diagnosed pancreatic invasive ductal carcinoma 2) No distant metastasis 3) T4 (UICC) 4) No evidence of gastro-duodenal ulcer 5) Age between 20 and 80 years old 6) PS 0-2 7) No past history of treatment for pancreatic cancer 8) Sufficient major organ function 9) Informed consent by patient

Exclusion criteria

Exclusion criteria: 1) Invasion to mucosal membrane of stomach or intestine 2) Ascites on CT scan 3) Metallic stent at the bile duct 4) Use of flu cytosine, phenytoin, or warfarin potassium 5) Uncontrolled severe infection 6) Uncontrolled severe complication 7) Active double cancers 8) Past history of irradiation to the target region 9) Other medical or psychological unsuitable reasons

Design outcomes

Primary

Measure	Time frame
two year survival rate	—

Secondary

Measure	Time frame
local control rate, progression free survival, complication rate	—

Countries

Japan

Contacts

Public ContactKotaro Terashima

SAGA HIMAT Foundation Ion Beam Therapy Center

terashima-kotaro@saga-himat.jp0942-81-1897

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026